Making treatments available to patients who need them is the core of our business.

Immedica’s business model is built on a commercial platform with physical presence in Europe and the Middle East, and also a larger network of partners in Asia and South America. Our cross-functional teams bring together our many disciplines. Our commercial, medical and market access teams work with healthcare professionals, external researchers, patient organizations and other stakeholders to increase understanding of patients’ and healthcare professionals’ changing needs.

Immedica has a network of CMOs for manufacturing of both drug substances and drug products. Patients should not risk being without treatment and that is why we have built stable processes for delivery and distribution to reach all patients in all our regions. Our business model is built on partnerships. We have a history of successful acquisitions, in-licensing deals, and exclusive distribution agreements. Partnerships are essential in our efforts to build and expand our product portfolio with new niche indications within two focus areas genetic & metabolic diseases and hematologic & oncology. Earnings from our commercial business are reinvested in the company to support our continued growth and access to new innovative treatments for patients.

Our principal philosophy is that everything we do should add value for our customers and partners and most importantly the patients.

Further growth in our therapeutic areas

We will continue to develop our three therapeutic areas: Genetic and metabolic diseases, Oncology and Hematology and Specialty care. During 2022, we recorded strong growth across the mature product portfolio.

Continue to build a best-in-class launch platform

Immedica has a track record of best-in-class commercialization. We have an experienced team offering a complete set of commercial pharmaceutical capabilities and have commercial field presence in all key European countries as well as an office in Dubai covering the Middle East and the North African region. This combined with a global distribution network enables Immedica to supply products to patients in more than 50 countries.

Continue to deliver excellence in partnering

Since 2018, Immedica has executed 15 successful deals including acquisition of assets, strategic licensing as well as distribution agreements. Immedica gives all partners full commitment and support. A close collaboration, efficient processes, transparent communication, and a problem-solving approach are all key factors for a successful project.